Selfdiagnostics’ work within the frames of Horizon 2020 project was evaluated by European Commission experts and an interim assessment report was recently completed. The experts found that our project is compliant with H2020 regulations and has achieved objectives and milestones set for the reporting period. Experts have confidence that Selfdiagnostics will provide results with significant immediate or potential impact in the next reporting period. Meaning that the project’s target to bring the first non-instrumented nucleic acid amplification (NINAAT) test device onto the market is in its final stage. The prototype is ready for analytical and clinical validation and soon, will be available for test users (lay users) and small series production.

Horizon 2020 is the biggest EU Research and Innovation programme and the financial instrument aimed at securing Europe’s global competitiveness. Selfdiagnostics entered the SME sub-programme in 2015 and was evaluated as one of the most promising applicants, ranking 9th among more than 600 applicants. Horizon 2020 has granted Selfdiagnostics €4.52 million to bring the test device to the market.

Selfdiagnostics OÜ | Deutscher Pl. 5D, 04103 Leipzig, Germany